

APPENDIX 2

ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS

Methods

The x-axis of the activity profile represents the bioassays in phylogenetic sequence by endpoint, and the values on the y-axis represent the logarithmically transformed lowest effective doses (LED) and highest ineffective doses (HID) tested. The term 'dose', as used in this report, does not take into consideration length of treatment or exposure and may therefore be considered synonymous with concentration. In practice, the concentrations used in all the in-vitro tests were converted to $\mu\text{g}/\text{ml}$, and those for in-vivo tests were expressed as $\text{mg}/\text{kg bw}$. Because dose units are plotted on a log scale, differences in molecular weights of compounds do not, in most cases, greatly influence comparisons of their activity profiles. Conventions for dose conversions are given below.

Profile-line height (the magnitude of each bar) is a function of the LED or HID, which is associated with the characteristics of each individual test system – such as population size, cell-cycle kinetics and metabolic competence. Thus, the detection limit of each test system is different, and, across a given activity profile, responses will vary substantially. No attempt is made to adjust or relate responses in one test system to those of another.

Line heights are derived as follows: for negative test results, the highest dose tested without appreciable toxicity is defined as the HID. If there was evidence of extreme toxicity, the next highest dose is used. A single dose tested with a negative result is considered to be equivalent to the HID. Similarly, for positive results, the LED is recorded. If the original data were analysed statistically by the author, the dose recorded is that at which the response was significant ($p < 0.05$). If the available data were not analysed statistically, the dose required to produce an effect is estimated as follows: when a dose-related positive response is observed with two or more doses, the lower of the doses is taken as the LED; a single dose resulting in a positive response is considered to be equivalent to the LED.

In order to accommodate both the wide range of doses encountered and positive and negative responses on a continuous scale, doses are transformed logarithmically, so that effective (LED) and ineffective (HID) doses are represented by positive and negative numbers, respectively. The response, or logarithmic dose unit (LDU_{ij}), for a given test system i and chemical j is represented by the expressions

$$\text{LDU}_{ij} = -\log_{10} (\text{dose}), \text{ for HID values; } \text{LDU} \leq 0$$

and

(1)

$$\text{LDU}_{ij} = -\log_{10} (\text{dose} \times 10^{-5}), \text{ for LED values; } \text{LDU} \geq 0.$$

These simple relationships define a dose range of 0 to -5 logarithmic units for ineffective doses (1–100 000 µg/ml or mg/kg bw) and 0 to +8 logarithmic units for effective doses (100 000–0.001 µg/ml or mg/kg bw). A scale illustrating the LDU values is shown in Figure 1. Negative responses at doses less than 1 µg/ml (mg/kg bw) are set equal to 1. Effectively, an LED value $\geq 100 000$ or an HID value ≤ 1 produces an LDU = 0; no quantitative information is gained from such extreme values. The dotted lines at the levels of log dose units 1 and -1 define a ‘zone of uncertainty’ in which positive results are reported at such high doses (between 10 000 and 100 000 µg/ml or mg/kg bw) or negative results are reported at such low dose levels (1 to 10 µg/ml or mg/kg bw) as to call into question the adequacy of the test.

Fig. 1. Scale of log dose units used on the y-axis of activity profiles

Positive (µg/ml or mg/kg bw)	Log dose units
0.001	8
0.01	7
0.1	6
1.0	5
10	4
100	3
1000	2
10 000	1
100 000	0
..... 1	-1
..... 10	-2
..... 100	-3
..... 1000	-4
..... 10 000	-5
..... 100 000	---

Negative (µg/ml or mg/kg bw)

LED and HID are expressed as µg/ml or mg/kg bw.

In practice, an activity profile is computer generated. A data entry programme is used to store abstracted data from published reports. A sequential file (in ASCH) is created for each compound, and a record within that file consists of the name and Chemical Abstracts Service number of the compound, a three-letter code for the test system (see below), the qualitative test result (with and without an exogenous metabolic system), dose (LED or HID), citation number and additional source information. An abbreviated citation for each publication is stored in a segment of a record accessing both the test data file and the citation file. During processing of the data file, an average of the logarithmic values of the data subset is calculated, and the length of the profile line represents this average value. All dose values are plotted for each profile line, regardless of whether results are positive or negative. Results obtained in the absence of an exogenous metabolic system are indicated by a bar (-), and results obtained in the presence of an exogenous metabolic system are indicated by an

upward-directed arrow (\uparrow). When all results for a given assay are either positive or negative, the mean of the LDU values is plotted as a solid line; when conflicting data are reported for the same assay (i.e., both positive and negative results), the majority data are shown by a solid line and the minority data by a dashed line (drawn to the extreme conflicting response). In the few cases in which the numbers of positive and negative results are equal, the solid line is drawn in the positive direction and the maximal negative response is indicated with a dashed line.

Profile lines are identified by three-letter code words representing the commonly used tests. Code words for most of the test systems in current use in genetic toxicology were defined for the US Environmental Protection Agency's GENE-TOX Program (Waters, 1979; Waters & Auletta, 1981). For this publication, codes were redefined in a manner that should facilitate inclusion of additional tests in the future. If a test system is not defined precisely, a general code is used that best defines the category of the test. Naming conventions are described below.

Dose conversions for activity profiles

Doses are converted to $\mu\text{g}/\text{ml}$ for in-vitro tests and to $\text{mg}/\text{kg bw}$ per day for in-vivo experiments.

1. In-vitro test systems

- (a) Weight/volume converts directly to $\mu\text{g}/\text{ml}$.
- (b) Molar (M) concentration \times molecular weight = $\text{mg}/\text{ml} = 10^3 \mu\text{g}/\text{ml}$; mM concentration \times molecular weight = $\mu\text{g}/\text{ml}$.
- (c) Soluble solids expressed as % concentration are assumed to be in units of mass per volume (i.e., 1% = $0.01 \text{ g}/\text{ml} = 10\,000 \mu\text{g}/\text{ml}$; also, 1 ppm = $1 \mu\text{g}/\text{ml}$).
- (d) Liquids and gases expressed as % concentration are assumed to be given in units of volume per volume. Liquids are converted to weight per volume using the density (D) of the solution (D = g/ml). If the bulk of the solution is water, then D = $1.0 \text{ g}/\text{ml}$. Gases are converted from volume to mass using the ideal gas law, $PV = nRT$. For exposure at $20\text{--}37^\circ\text{C}$ at standard atmospheric pressure, 1% (v/v) = $0.4 \mu\text{g}/\text{ml} \times$ molecular weight of the gas. Also, 1 ppm (v/v) = $4 \times 10^{-5} \mu\text{g}/\text{ml} \times$ molecular weight.
- (e) For microbial plate tests, concentrations reported as weight/plate are divided by top agar volume (if volume is not given, a 2-ml top agar is assumed). For spot tests, in which concentrations are reported as weight or weight/disc, a 1-ml volume is used as a rough approximation.
- (f) Conversion of asbestos concentrations given in $\mu\text{g}/\text{cm}^2$ are based on the area (A) of the dish and the volume of medium per dish; i.e., for a 100-mm dish: $A = \pi R^2 = \pi \times (5\text{cm})^2 = 78.5 \text{ cm}^2$. If the volume of medium is 10 ml, then $78.5 \text{ cm}^2 = 10 \text{ ml}$ and $1 \text{ cm}^2 = 0.13 \text{ ml}$.

2. In-vitro systems using in-vivo activation

For the body fluid-urine (BF-) test, the concentration used is the dose (in $\text{mg} \cdot \text{kg bw}$) of the compound administered to test animals or patients.

3. In-vivo test systems

- (a) Doses are converted to mg/kg bw per day of exposure, assuming 100% absorption. Standard values are used for each sex and species of rodent, including body weight and average intake per day, as reported by Gold *et al.* (1984). For example, in a test using male mice fed 50 ppm of the agent in the diet, the standard food intake per day is 12% of body weight, and the conversion is dose = 50 ppm × 12% = 6 mg/kg bw per day. Standard values used for humans are: weight - males, 70 kg; females, 55 kg; surface area, 1.7 m²; inhalation rate, 20 l/min for light work, 30 l/min for mild exercise.
- (b) When reported, the dose at the target site is used. For example, doses given in studies of lymphocytes of humans exposed *in vivo* are the measured blood concentrations in µg/ml.

Codes for test systems

For specific nonmammalian test systems, the first two letters of the three-symbol code word define the test organism (e.g., SA- for *Salmonella typhimurium*, EC- for *Escherichia coli*). In most cases, the first two letters accurately represent the scientific name of the organism. If the species is not known, the convention used is -S-. The third symbol may be used to define the tester strain (e.g., SA8 for *S. typhimurium* TA1538, ECW for *E. coli* WP2uvrA). When strain designation is not indicated, the third letter is used to define the specific genetic endpoint under investigation (e.g., —D for differential toxicity, —F for forward mutation, —G for gene conversion or genetic crossing-over, —N for aneuploidy, —R for reverse mutation, —U for unscheduled DNA synthesis). The third letter may also be used to define the general endpoint under investigation when a more complete definition is not possible or relevant (e.g., —M for mutation, —C for chromosomal aberration).

For mammalian test systems, the first letter of the three-letter code word defines the genetic endpoint under investigation: A— for aneuploidy, B— for binding, C— for chromosomal aberration, D— for DNA strand breaks, G— for gene mutation, I— for inhibition of intercellular communication, M— for micronucleus formation, R— for DNA repair, S— for sister chromatid exchange, T— for cell transformation and U— for unscheduled DNA synthesis.

For animal (i.e., nonhuman) test systems *in vitro*, when the cell type is not specified, the code letters -IA are used. For such assays *in vivo*, when the animal species is not specified, the code letters -VA are used. Commonly used animal species are identified by the third letter (e.g., —C for Chinese hamster, —M for mouse, —R for rat, —S for Syrian hamster).

For test systems using human cells *in vitro*, when the cell type is not specified, the code letters -IH are used. For assays on humans *in vivo*, when the cell type is not specified, the code letters -VH are used. Otherwise, the second letter specifies the cell type under investigation (e.g., -BH for bone marrow, -LH for lymphocytes).

Some other specific coding conventions used for mammalian systems are as follows: BF- for body fluids, HM- for host-mediated, —L for leucocytes or lymphocytes *in vitro*

(-AL, animals; -HL, humans), -L- for leucocytes *in vivo* (-LA, animals; -LH, humans), --T for transformed cells.

Note that these are examples of major conventions used to define the assay code words. The alphabetized listing of codes must be examined to confirm a specific code word. As might be expected from the limitation to three symbols, some codes do not fit the naming conventions precisely. In a few cases, test systems are defined by first-letter code words, for example: MST, mouse spot test; SLP, mouse specific locus test, postspermatogonia; SLO, mouse specific locus test, other stages; DLM, dominant lethal test in mice; DLR, dominant lethal test in rats; MHT, mouse heritable translocation test.

The genetic activity profiles and listings that follow were prepared in collaboration with Environmental Health Research and Testing Inc. (EHRT) under contract to the US Environmental Protection Agency; EHRT also determined the doses used. The references cited in each genetic activity profile listing can be found in the list of references in the appropriate monograph.

References


- Garrett, N.E., Stack, H.F., Gross, M.R. & Waters, M.D. (1984) An analysis of the spectra of genetic activity produced by known or suspected human carcinogens. *Mutat. Res.*, 134, 89-111
- Gold, L.S., Sawyer, C.B., Magaw, R., Backman, G.M., de Veciana, M., Levinson, R., Hooper, N.K., Ha-vender, W.R., Bernstein, L., Peto, R., Pike, M.C. & Ames, B.N. (1984) A carcinogenic potency database of the standardized results of animal bioassays. *Environ. Health Perspect.*, 58, 9-319
- Waters, M.D. (1979) *The GENE-TOX program*. In: Hsie, A.W., O'Neill, J.P. & McElheny, V.K., eds, *Mammalian Cell Mutagenesis: The Maturation of Test Systems (Banbury Report 2)*, Cold Spring Harbor, NY, CHS Press, pp. 449-467
- Waters, M.D. & Auletta, A. (1981) The GENE-TOX program: genetic activity evaluation. *J. chem. Inf. comput. Sci.*, 21, 35-38

TOLUENE

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
D	PRB	PROPHAGE, INDUCT/SOS/STRAND BREAKS/X-LINKS	-	100.0000	NAKAMURA ET AL., 1987
D	ECL	E. COLI POL A, DIFFERENTIAL TOX (LIQUID)	-	400000.0000	MCCARROLL ET AL., 1981b
D	ERD	E. COLI REC, DIFFERENTIAL TOXICITY	-	400000.0000	MCCARROLL ET AL., 1981b
D	BSD	B. SUBTILIS REC, DIFFERENTIAL TOXICITY	-	127000.0000	MCCARROLL ET AL., 1981a
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	2500.0000	SPANGGORD ET AL., 1982
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	1000.0000	BOS ET AL., 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	2150.0000	NESTMANN ET AL., 1980
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	1000.0000	CONNOR ET AL., 1985
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	167.0000	HAWORTH ET AL., 1983
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	2500.0000	SPANGGORD ET AL., 1982
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	2150.0000	NESTMANN ET AL., 1980
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	1000.0000	BOS ET AL., 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	167.0000	HAWORTH ET AL., 1983
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	2500.0000	SPANGGORD ET AL., 1982
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	2150.0000	NESTMANN ET AL., 1980
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	1000.0000	BOS ET AL., 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	167.0000	HAWORTH ET AL., 1983
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	2150.0000	NESTMANN ET AL., 1980
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	2500.0000	SPANGGORD ET AL., 1982
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	1000.0000	BOS ET AL., 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	1000.0000	BOS ET AL., 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	2500.0000	SPANGGORD ET AL., 1982
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	2150.0000	NESTMANN ET AL., 1980
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	1000.0000	CONNOR ET AL., 1985
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	167.0000	HAWORTH ET AL., 1983
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	-	1000.0000	CONNOR ET AL., 1985
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	- 0	13000.0000	RODRIGUEZ ARNAIZ & VILLALOBOS-PIETRINI, 1985b
C	DMH	D. MELANOGASTER, HERITABLE TRANSLOCATIONS	- 0	13000.0000	RODRIGUEZ ARNAIZ & VILLALOBOS-PIETRINI, 1985b
A	DMN	D. MELANOGASTER, ANEUPLOIDY	+ 0	8700.0000	RODRIGUEZ ARNAIZ & VILLALOBOS-PIETRINI, 1985a
D	DIA	STRAND BREAKS/X-LINKS, ANIMAL CELLS IN VITRO	+ 0	3.0000	SINA ET AL., 1983
T	T7S	CELL TRANSFORMATION, SA7/SHE CELLS	- 0	1000.0000	CASTO, 1981
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	- 0	1500.0000	GERNER-SMIDT & FRIEDRICH, 1978
C	CHL	CHROM ABERR, HUMAN LYMPHOCYTES IN VITRO	- 0	1500.0000	GERNER-SMIDT & FRIEDRICH, 1978
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	+ 0	0.1200	MONTASHAMIPUR ET AL., 1985
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	- 0	1700.0000	GAD-EL-KARIM ET AL., 1984
M	MVR	MICRONUCLEUS TEST, RATS IN VIVO	+ 0	200.0000	ROH ET AL., 1987
C	CBA	CHROM ABERR, ANIMAL BONE MARROW IN VIVO	+ 0	1000.0000	LYAPKALO, 1973
C	CBA	CHROM ABERR, ANIMAL BONE MARROW IN VIVO	+ 0	400.0000	ROH ET AL., 1987
C	CBA	CHROM ABERR, ANIMAL BONE MARROW IN VIVO	+ 0	800.0000	DOBROKHOTOV, 1972
C	CBA	CHROM ABERR, ANIMAL BONE MARROW IN VIVO	+ 0	0.0000	ARISTOV ET AL., 1981
C	CBA	CHROM ABERR, ANIMAL BONE MARROW IN VIVO	- 0	1700.0000	GAD-EL-KARIM ET AL., 1984
S	SLH	SCE, HUMAN LYMPHOCYTES IN VIVO	+ 0	75.0000	BAUCHINGER ET AL., 1982
S	SLH	SCE, HUMAN LYMPHOCYTES IN VIVO	- 0	14.0000	HAGLUND ET AL., 1980
S	SLH	SCE, HUMAN LYMPHOCYTES IN VIVO	- 0	40.0000	MAKI-PAAKKANEN ET AL., 198
C	CLH	CHROM ABERR, HUMAN LYMPHOCYTES IN VIVO	+ 0	75.0000	BAUCHINGER ET AL., 1982
C	CLH	CHROM ABERR, HUMAN LYMPHOCYTES IN VIVO	- 0	40.0000	MAKI-PAAKKANEN ET AL., 198
C	CLH	CHROM ABERR, HUMAN LYMPHOCYTES IN VIVO	- 0	75.0000	FORNI ET AL., 1971
C	CLH	CHROM ABERR, HUMAN LYMPHOCYTES IN VIVO	- 0	0.0000	PELCLOVA ET AL., 1987
P	SPM	SPERM MORPHOLOGY, MICE	- 0	900.0000	TOPHAM, 1980

APPENDIX 2

455



XYLEMES

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM M (LED OR HID)	DOSE	REFERENCE	
D	PRB	PROPHAGE, INDUCT/SOS/STRAND BREAKS/X-LINKS	- -	36.0000	NAKAMURA ET AL., 1987	(us)
D	ECL	E. COLI POL A, DIFFERENTIAL TOX (LIQUID)	- -	10000.0000	MCCARROLL ET AL., 1981b	(tg)
D	ERD	E. COLI REC, DIFFERENTIAL TOXICITY	- -	10000.0000	MCCARROLL ET AL., 1981b	(tg)
D	BSD	B. SUBTILIS REC, DIFFERENTIAL TOXICITY	- -	100000.0000	MCCARROLL ET AL., 1981a	(tg)
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	100.0000	ZEIGER ET AL., 1987	(x)
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	50.0000	SHIMIZU ET AL., 1985	(p)
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	250.0000	BOS ET AL., 1981	(o,m,p)
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	166.0000	HAWORTH ET AL., 1983	(o)
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	16.0000	HAWORTH ET AL., 1983	(m)
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	100.0000	HAWORTH ET AL., 1983	(p)
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	500.0000	CONNOR ET AL., 1985	(o,m,p)
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	100.0000	ZEIGER ET AL., 1987	(x)
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	166.0000	HAWORTH ET AL., 1983	(o)
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	16.0000	HAWORTH ET AL., 1983	(m)
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	100.0000	HAWORTH ET AL., 1983	(p)
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	50.0000	SHIMIZU ET AL., 1985	(p)
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	250.0000	BOS ET AL., 1981	(o,m,p)
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	50.0000	SHIMIZU ET AL., 1985	(p)
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	166.0000	HAWORTH ET AL., 1983	(o)
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	16.0000	HAWORTH ET AL., 1983	(m)
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	100.0000	HAWORTH ET AL., 1983	(p)
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	250.0000	BOS ET AL., 1981	(o,m,p)
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	250.0000	BOS ET AL., 1981	(o,m,p)
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	100.0000	ZEIGER ET AL., 1987	(x)
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	250.0000	BOS ET AL., 1981	(o,m,p)
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	50.0000	SHIMIZU ET AL., 1985	(p)
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	166.0000	HAWORTH ET AL., 1983	(o)
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	16.0000	HAWORTH ET AL., 1983	(m)
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	100.0000	HAWORTH ET AL., 1983	(p)
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	500.0000	CONNOR ET AL., 1985	(o,m,p)
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	- -	100.0000	ZEIGER ET AL., 1987	(x)
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	- -	500.0000	CONNOR ET AL., 1985	(o,m,p)
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	- -	50.0000	SHIMIZU ET AL., 1985	(p)
T	T7S	CELL TRANSFORMATION, SA7/SHE CELLS	- 0	1000.0000	CASTO, 1981	(us)
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	- 0	1500.0000	GERNER-SMIDT & FRIEDRICH, 1978	(us)
C	CHL	CHROM ABERR, HUMAN LYMPHOCYTES IN VITRO	- 0	1500.0000	GERNER-SMIDT & FRIEDRICH, 1978	(us)
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	- 0	400.0000	MOHTASHAMIPUR ET AL., 1985	(o)
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	- 0	650.0000	MOHTASHAMIPUR ET AL., 1985	(m,p)
S	SLH	SCE, HUMAN LYMPHOCYTES IN VIVO	- 0	10.0000	HAGLUND ET AL., 1980	(us)
S	SLH	SCE, HUMAN LYMPHOCYTES IN VIVO	- 0	55.0000	PAP & VARGA ET AL., 1987	(tg)
P	SPR	SPERM MORPHOLOGY, RATS	(+) 0	400.0000	WASHINGTON ET AL., 1983	(o)

o — ortho

m — meta


p — para

us — unspecified

x — mixture of isomers


tg — technical grade

APPENDIX 2



CYCLOHEXANONE

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	5000.0000	HAWORTH ET AL., 1983
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	5000.0000	HAWORTH ET AL., 1983
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	5000.0000	HAWORTH ET AL., 1983
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	5000.0000	HAWORTH ET AL., 1983
C	CHL	CHROM ABERR, HUMAN LYMPHOCYTES IN VITRO	+ 0	0.0000	COLLIN, 1971
C	CHL	CHROM ABERR, HUMAN LYMPHOCYTES IN VITRO	+ 0	10.0000	LEDERER ET AL., 1971
C	CHL	CHROM ABERR, HUMAN LYMPHOCYTES IN VITRO	+ 0	0.0050	DYSHLOVOI ET AL., 1981
A	AIH	ANEUPLOIDY, HUMAN CELLS IN VITRO	+ 0	0.0050	DYSHLOVOI ET AL., 1981
C	CBA	CHROM ABERR, ANIMAL BONE MARROW IN VIVO	+ 0	100.0000	DE HONDT ET AL., 1983



25-OCT-89

DIMETHYLFORMAMIDE

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
D	ECL	E. COLI POL A, DIFFERENTIAL TOX (LIQUID)	- -	2300.0000	ROSENKRANZ ET AL., 1981
D	ERD	E. COLI REC, DIFFERENTIAL TOXICITY	- -	0.0000	GREEN, 1981
D	ERD	E. COLI REC, DIFFERENTIAL TOXICITY	- 0	0.0000	ICHINOTSUBO ET AL., 1981a
D	ERD	E. COLI REC, DIFFERENTIAL TOXICITY	- -	0.0000	TWEATS, 1981
D	BSD	B. SUBTILIS REC, DIFFERENTIAL TOXICITY	- -	19000.0000	KADA, 1981
G	SAF	S. TYPHIMURIUM, FORWARD MUTATION	0 -	1000.0000	SKOPEK ET AL., 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	0 -	1250.0000	PURCHASE ET AL., 1978
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	94.0000	ANTOINE ET AL., 1983
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	0 -	1000.0000	FALCK ET AL., 1985
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	5000.0000	MORTELMANS ET AL., 1986
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	2500.0000	MACDONALD, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- 0	0.0000	ICHINOTSUBO ET AL., 1981b
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	0.0000	NAGAO & TAKAHASHI, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	5000.0000	RICHOLD & JONES, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	1000.0000	ROWLAND & SEVERN, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	1250.0000	TRUEMAN, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	250.0000	VENITT & CROFTON-SLEIGH, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- ?	500.0000	HUBBARD ET AL., 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	1000.0000	BROOKS & DEAN, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	500.0000	BAKER & BONIN, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	0.0000	SIMMON & SHEPHERD, 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	0 -	1250.0000	PURCHASE ET AL., 1978
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	94.0000	ANTOINE ET AL., 1983
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	0 -	1000.0000	FALCK ET AL., 1985
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	5000.0000	MORTELMANS ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	5000.0000	RICHOLD & JONES, 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	1000.0000	ROWLAND & SEVERN, 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	1250.0000	TRUEMAN, 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	1000.0000	GATEHOUSE, 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	1000.0000	BROOKS & DEAN, 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	500.0000	BAKER & BONIN, 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	0.0000	SIMMON & SHEPHERD, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	94.0000	ANTOINE ET AL., 1983
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	0 -	500.0000	FALCK ET AL., 1985
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	5000.0000	MORTELMANS ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	0.0000	NAGAO & TAKAHASHI, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	5000.0000	RICHOLD & JONES, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	1000.0000	ROWLAND & SEVERN, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	1250.0000	TRUEMAN, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	5000.0000	MACDONALD, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	1000.0000	GATEHOUSE, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	1000.0000	BROOKS & DEAN, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	500.0000	BAKER & BONIN, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	0.0000	SIMMON & SHEPHERD, 1981
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	0 -	1250.0000	PURCHASE ET AL., 1978
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	94.0000	ANTOINE ET AL., 1983
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	0 -	1000.0000	FALCK ET AL., 1985
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	5000.0000	RICHOLD & JONES, 1981
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	1000.0000	ROWLAND & SEVERN, 1981
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- +	0.0000	TRUEMAN, 1981

APPENDIX 2

461

DIMETHYLFORMAMIDE


END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
					NM M (LED OR HID)
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	1000.0000	BROOKS & DEAN, 1981
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	500.0000	BAKER & BONIN, 1981
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	0.0000	SIMMON & SHEPHERD, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	0 -	1250.0000	PURCHASE ET AL., 1978
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	94.0000	ANTOINE ET AL., 1983
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	0 -	1000.0000	FALCK ET AL., 1985
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	5000.0000	MORTELMANS ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	5000.0000	MACDONALD, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- 0	0.0000	ICHINOTSUBO ET AL., 1981b
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	0.0000	NAGAO & TAKAHASHI, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	5000.0000	RICHOLD & JONES, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	1000.0000	ROWLAND & SEVERN, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- +	250.0000	TRUEMAN, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	250.0000	VENITT & CROFTON-SLEIGH, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- ?	500.0000	HUBBARD ET AL., 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	1000.0000	GATEHOUSE, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	1000.0000	BROOKS & DEAN, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	500.0000	BAKER & BONIN, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	0.0000	SIMMON & SHEPHERD, 1981
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	0 -	73000.0000	GREEN & SAVAGE, 1978
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	- -	1000.0000	BROOKS & DEAN, 1981
G	ECF	E. COLI (EXCLUDING K12), FORWARD MUTATION	0 -	4000.0000	MOHN ET AL., 1981
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	0 -	1000.0000	FALCK ET AL., 1985
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	- -	250.0000	VENITT & CROFTON-SLEIGH, 1981
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	- -	500.0000	GATEHOUSE, 1981
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	- -	0.0000	MATSUSHIMA ET AL., 1981
D	SSB	SACCHAROMYCES, STRAND BREAKS/X-LINKS	- -	1000.0000	KOSSINOVA ET AL., 1981
D	SSD	SACCHAROMYCES, DIFFERENTIAL TOXICITY	+ +	500.0000	SHARP & PARRY, 1981a
R	SCH	S. CEREVISIAE, HOMOZYGOsis	- -	500.0000	SHARP & PARRY, 1981b
R	SCH	S. CEREVISIAE, HOMOZYGOsis	+ +	4700.0000	ZIMMERMANN & SCHEEL, 1981
R	SCH	S. CEREVISIAE, HOMOZYGOsis	- -	167.0000	JAGANNATH ET AL., 1981
R	SCH	S. CEREVISIAE, HOMOZYGOsis	- -	1000.0000	KASSINOVA ET AL., 1981
G	SCF	S. CEREVISIAE, FORWARD MUTATION	- -	800.0000	MEHTA & VON BORSTEL, 1981
G	SZF	S. POMBE, FORWARD MUTATION	- -	20.0000	LOPRIENO, 1981
A	SCN	S. CEREVISIAE, ANEUPLOIDY	+ +	100.0000	PARRY & SHARP, 1981
G	ASM	ARABIDOPSIS SPECIES, MUTATION	- 0	300000.0000	GICHNER & VELEMINSKY, 1987
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	- 0	900.0000	WURGLER & GRAF, 1981
D	URP	UDS, RAT PRIMARY HEPATOCYTES	(+) 0	700.0000	WILLIAMS, 1977
D	URP	UDS, RAT PRIMARY HEPATOCYTES	- 0	7300.0000	WILLIAMS & LASPIA, 1979
D	URP	UDS, RAT PRIMARY HEPATOCYTES	- 0	70.0000	ITO, 1982
D	UIA	UDS, OTHER ANIMAL CELLS IN VITRO	- 0	700.0000	MCQUEEN ET AL., 1983
D	UIA	UDS, OTHER ANIMAL CELLS IN VITRO	- 0	70.0000	KLAUNIG ET AL., 1984
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	(+) -	5000.0000	MCGREGOR ET AL., 1988
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	- -	4700.0000	MITCHELL ET AL., 1988
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	(+) -	3000.0000	JOTZ & MITCHELL, 1981
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	- -	4700.0000	MYHR & CASPARY, 1988
S	SIC	SCE, CHINESE HAMSTER CELLS IN VITRO	- -	100.0000	PERRY & THOMSON, 1981
S	SIC	SCE, CHINESE HAMSTER CELLS IN VITRO	- -	900.0000	EVANS & MITCHELL, 1981
S	SIC	SCE, CHINESE HAMSTER CELLS IN VITRO	- -	6300.0000	NATARAJAN & VAN KESTEREN-VAN LEEUWEN, 198
C	CIC	CHROM ABERR, CHINESE HAMSTER CELLS IN VITRO	- -	6300.0000	NATARAJAN & VAN KESTEREN-VAN LEEUWEN, 198

DIMETHYLFORMAMIDE

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
C	CIR	CHROM ABERR, RAT CELLS IN VITRO	-	0	300.0000 DEAN, 1981
D	UHF	UDS, HUMAN FIBROBLASTS IN VITRO	-	-	90.0000 ROBINSON & MITCHELL, 1981
D	UHF	UDS, HUMAN FIBROBLASTS IN VITRO	0	-	0.0000 AGRELO & AMOS, 1981
D	UHF	UDS, HUMAN FIBROBLASTS IN VITRO	-	-	100.0000 MARTIN & MCDERMID, 1981
G	GIH	MUTATION, HUMAN CELLS IN VITRO	-	-	500.0000 GUPTA & GOLDSTEIN, 1981
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	-	0	80000.0000 ANTOINE ET AL., 1983
C	CHL	CHROM ABERR, HUMAN LYMPHOCYTES IN VITRO	-	0	80000.0000 ANTOINE ET AL., 1983
C	CHL	CHROM ABERR, HUMAN LYMPHOCYTES IN VITRO	+	0	0.0070 KOUDELA & SPAZIER ET AL., 1979
S	SVA	SCE, ANIMALS IN VIVO	-	0	2500.0000 PAIKA ET AL., 1981
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	-	0	2.5000 SALAMONE ET AL., 1981
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	-	0	1600.0000 KIRKHART, 1981
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	-	0	1500.0000 TSUCHIMOTO & MATTER, 1981
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	-	0	2000.0000 ANTOINE ET AL., 1983
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	+	0	1.0000 YE ET AL., 1987
C	CLH	CHROM ABERR, HUMAN LYMPHOCYTES IN VIVO	+	0	0.0000 BERGER ET AL., 1985
C	CLH	CHROM ABERR, HUMAN LYMPHOCYTES IN VIVO	+	0	0.0000 KOUDELA & SPAZIER ET AL., 1981
P	SPM	SPERM MORPHOLOGY, MICE	-	0	667.0000 ANTOINE ET AL., 1983
P	SPM	SPERM MORPHOLOGY, MICE	-	0	900.0000 TOPHAM, 1980
I	ICR	INHIBIT CELL COMMUNICATION, ANIMAL CELLS	+	0	3800.0000 CHEN ET AL., 1984


Dimethylformamide was one of the compounds tested in 17 studies on mutation in bacteria in the International Collaborative Program for the Evaluation of Short-term Tests for Carcinogens (de Serres & Ashby, 1981). In two of the studies, results for dimethylformamide were not reported directly, so these are not included in the above listing.

APPENDIX 2



MORPHOLINE

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	5450.0000	HAWORTH ET AL., 1983
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	5000.0000	ISHIDATE ET AL., 1984
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	5450.0000	HAWORTH ET AL., 1983
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	5000.0000	ISHIDATE ET AL., 1984
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	5450.0000	HAWORTH ET AL., 1983
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	5000.0000	ISHIDATE ET AL., 1984
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	1800.0000	HAWORTH ET AL., 1983
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	5000.0000	ISHIDATE ET AL., 1984
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	-	5000.0000	ISHIDATE ET AL., 1984
D	URP	UDS, RAT PRIMARY HEPATOCYTES	- 0	100.0000	CONAWAY ET AL., 1984
C	CIC	CHROM ABERR, CHINESE HAMSTER CELLS IN VITRO	- 0	250.0000	ISHIDATE ET AL., 1984
H	HMM	HOST-MEDIATED ASSAY, MICROBIAL CELLS	- 0	250.0000	BRAUN ET AL., 1977
H	HMM	HOST-MEDIATED ASSAY, MICROBIAL CELLS	- 0	40.0000	EDWARDS ET AL., 1979
C	COE	CHROM ABERR, OOCYTES OR EMBRYOS	- 0	500.0000	INUI ET AL., 1979



1,2-EPOXYBUTANE


END POINT	TEST CODE	TEST SYSTEM	RESULTS		DOSE NM M (LED OR HID)	REFERENCE
			N	M		
D	PRB	PROPHAGE, INDUCT/SOS/STRAND BREAKS/X-LINKS	+	0	780.0000	NAKAMURA ET AL., 1987
D	ECL	E. COLI POL A, DIFFERENTIAL TOX (LIQUID)	+	0	20000.0000	MCCARROLL ET AL., 1981b
D	ECL	E. COLI POL A, DIFFERENTIAL TOX (LIQUID)	+	0	50.0000	ROSENKRANZ & POIRIER, 1979
D	ERD	E. COLI REC, DIFFERENTIAL TOXICITY	+	0	4300.0000	MCCARROLL ET AL., 1981b
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	0	0.0000	MCMAHON ET AL., 1979
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	(+)	0	2100.0000	MCCANN ET AL., 1975
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	0	7.0000	SPECK & ROSENKRANZ, 1976
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	0	2100.0000	HENSCHLER ET AL., 1977
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	-	167.0000	DUNKEL ET AL., 1984
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	-	250.0000	SIMMON, 1979a
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	+	2.5000	DE FLORA, 1979
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	+	2000.0000	DE FLORA, 1981
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	0	1100.0000	GERVASI ET AL., 1985
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	+	0.0000	DE FLORA ET AL., 1984
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	+	500.0000	CANTER ET AL., 1986
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	0	360.0000	ROSMAN ET AL., 1987
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	+	500.0000	NTP, 1988
G	SA3	S. TYPHIMURIUM TA1530, REVERSE MUTATION	+	0	17000.0000	CHEN ET AL., 1975
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	0	2100.0000	MCCANN ET AL., 1975
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	0.0000	DE FLORA ET AL., 1984
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	-	167.0000	DUNKEL ET AL., 1984
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	-	250.0000	SIMMON, 1979a
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	42.0000	ROSENKRANZ & POIRIER, 1979
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	1250.0000	WEINSTEIN ET AL., 1981
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	2000.0000	DE FLORA, 1981
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	500.0000	CANTER ET AL., 1986
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	0	90.0000	ROSMAN ET AL., 1987
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	500.0000	NTP, 1988
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	-	167.0000	DUNKEL ET AL., 1984
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	-	250.0000	SIMMON, 1979a
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	-	20000.0000	DE FLORA, 1981
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	-	5000.0000	CANTER ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	-	5000.0000	NTP, 1988
G	SAB	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	-	250.0000	SIMMON, 1979a
G	SAB	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	-	20000.0000	DE FLORA, 1981
G	SAB	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	-	167.0000	DUNKEL ET AL., 1984
G	SAB	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	-	5000.0000	NTP, 1988
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	20000.0000	DE FLORA, 1981
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0	2200.0000	GERVASI ET AL., 1985
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	5000.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	250.0000	SIMMON, 1979a
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	+	0	3.5000	ROSENKRANZ & SPECK, 1975
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	-	-	250.0000	SIMMON, 1979a
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	+	0	0.0000	MCMAHON ET AL., 1979
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	-	-	167.0000	DUNKEL ET AL., 1984
G	KPF	K. PNEUMONIA, FORWARD MUTATION	(+)	+	72.0000	VOOGD ET AL., 1981
G	KPF	K. PNEUMONIA, FORWARD MUTATION	+	0	72.0000	KNAAP ET AL., 1982
R	SCH	S. CEREVISIAE, HOMOZYGOSIS	+	+	5000.0000	SIMMON, 1979b
G	SZF	S. POMBE, FORWARD MUTATION	+	+	29.0000	MIGLIORE ET AL., 1982
G	NCR	N. CRASSA, REVERSE MUTATION	(+)	0	14.0000	KOLMARK & GILES, 1955

APPENDIX 2

467

1,2-EPOXYBUTANE

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	+	0	8400.0000 KNAAP ET AL., 1982
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	+	0	50000.0000 NTP, 1988
C	DMH	D. MELANOGASTER, HERITABLE TRANSLOCATIONS	+	0	50000.0000 NTP, 1988
D	URP	UDS, RAT PRIMARY HEPATOCYTES	-	0	1000.0000 WILLIAMS ET AL., 1982
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	+	0	63.0000 AMACHER ET AL., 1980
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	+	+	400.0000 MCGREGOR ET AL., 1987
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	+	+	55.0000 MITCHELL ET AL., 1988
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	+	+	50.0000 MYHR & CASPARY, 1985
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	+	+	50.0000 NTP, 1988
G	G51	MUTATION, L5178Y CELLS, ALL OTHER LOCI	+	0	360.0000 KNAAP ET AL., 1982
S	SIC	SCE, CHINESE HAMSTER CELLS IN VITRO	+	+	16.0000 NTP, 1988
C	CIC	CHROM ABERR, CHINESE HAMSTER CELLS IN VITRO	(+)	(+)	500.0000 NTP, 1988
T	TBM	CELL TRANSFORMATION, BALB/C3T3 CELLS	-	0	50.0000 DUNKEL ET AL., 1981
T	TCS	CELL TRANSFORMATION, SHE, CLONAL ASSAY	+	0	0.0000 PIENTA ET AL., 1981
T	TFS	CELL TRANSFORMATION, SHE, FOCUS ASSAY	(+)	0	50.0000 DUNKEL ET AL., 1981
T	TRR	CELL TRANSFORMATION, RLV/FISCHER RAT	+	0	10.0000 PRICE & MISHRA, 1980
T	TRR	CELL TRANSFORMATION, RLV/FISCHER RAT	+	0	700.0000 DUNKEL ET AL., 1981



APPENDIX 2


469

BIS(2,3-EPOXYCYCLOPENTYL)ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	1425.0000	XIE & DONG, 1984
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	+	30.0000	XIE & DONG, 1984
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	+	500.0000	XIE & DONG, 1984

BIS(2,3-EPOXYCYCLOPENTYL)ETHER
2386-90-5

25-OCT-89




APPENDIX 2

471

OCTYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	+	167.0000 THOMPSON ET AL., 1981
G	SAS	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	+	56.0000 THOMPSON ET AL., 1981
G	GST	MUTATION, L5178Y CELLS, TK LOCUS	-	-	225.0000 THOMPSON ET AL., 1981
D	UHF	UDS, HUMAN FIBROBLASTS IN VITRO	-	-	1400.0000 THOMPSON ET AL., 1981




APPENDIX 2

473

DECYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	+	100.0000 THOMPSON ET AL., 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	+	100.0000 THOMPSON ET AL., 1981
G	G5T	MUTATION, L5178Y CELLS, TK LOCUS	+	-	80.0000 THOMPSON ET AL., 1981
D	UHF	UDS, HUMAN FIBROBLASTS IN VITRO	-	-	6000.0000 THOMPSON ET AL., 1981




APPENDIX 2

475

DODECYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM M	DOSE (LED OR HID)	REFERENCE		
					-	+	-
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	150.0000	THOMPSON ET AL., 1981		
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	50.0000	THOMPSON ET AL., 1981		
G	GST	MUTATION, L5178Y CELLS, TK LOCUS	-	225.0000	THOMPSON ET AL., 1981		
D	UHF	UDS, HUMAN FIBROBLASTS IN VITRO	-	6000.0000	THOMPSON ET AL., 1981		




APPENDIX 2

477

TETRADECYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	2500.0000	THOMPSON ET AL., 1981
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	2500.0000	THOMPSON ET AL., 1981
G	G5T	MUTATION, LS17BY CELLS, TK LOCUS	-	200.0000	THOMPSON ET AL., 1981
D	UHF	UDS, HUMAN FIBROBLASTS IN VITRO	-	8000.0000	THOMPSON ET AL., 1981




APPENDIX 2

479

ALLYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	167.0000	CANTER ET AL., 1986
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	0.0000	WADE ET AL., 1979
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	50.0000	CANTER ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	0.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	5000.0000	WADE ET AL., 1979
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	+	0.0000	HEMMINKI ET AL., 1980
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	+	5280.0000	YOUN ET AL., 1985



APPENDIX 2

481


BISPHENOL A DIGLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	10000.0000	WADE ET AL., 1979
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+ 0	14.0000	ANDERSEN ET AL., 1978
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+ +	16.0000	CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+ +	92.0000	ANDERSEN ET AL., 1978
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+ +	167.0000	CANTER ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	0.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	10000.0000	WADE ET AL., 1979
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	0.0000	CANTER ET AL., 1986
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	+ 0	0.0000	HEMMINKI ET AL., 1980
C	CLH	CHROM ABERR, HUMAN LYMPHOCYTES IN VIVO	- 0	0.0000	MITELMAN ET AL., 1980

BISPHENOL A DIGLYCIDYL ETHER

1675-54-3

25-OCT-89



APPENDIX 2

483


1,4-BUTANEDIOL DIGLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	+	167.0000 CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	167.0000 CANTER ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	?	+	0.0000 CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	+	+	0.0000 CANTER ET AL., 1986

1,4-BUTANEDIOL DIGLYCIDYL ETHER

2425-79-8

25-OCT-89




APPENDIX 2

485

n-BUTYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	10000.0000	WADE ET AL., 1979
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	50.0000	CANTER ET AL., 1986
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	0	130.0000 CONNOR ET AL., 1980b
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	167.0000	CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	0	65.0000 CONNOR ET AL., 1980b
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	0	130.0000 CONNOR ET AL., 1980b
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	0	130.0000 CONNOR ET AL., 1980b
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	50.0000 WADE ET AL., 1979
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	1667.0000 CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0	130.0000 CONNOR ET AL., 1980b
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	+	0.0000	CANTER ET AL., 1986
T	TBM	CELL TRANSFORMATION, BALB/C3T3 CELLS	-	0	670.0000 CONNOR ET AL., 1980b
F	BFA	ANIMAL BODY FLUIDS, MICROBIAL MUTAGENICITY	-	0	200.0000 CONNOR ET AL., 1980b
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	+	0	675.0000 CONNOR ET AL., 1980b
C	DLM	DOMINANT LETHAL TEST, MICE	(+)	0	1.5000 WHORTON ET AL., 1983




APPENDIX 2

487

t-BUTYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS		DOSE NM M (LED OR HID)	REFERENCE
			N	M		
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	+	50.0000	CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	+	167.0000	CANTER ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	(+)	0.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	?	(+)	0.0000	CANTER ET AL., 1986




t-BUTYLPHENYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	-	5.0000 CANTER ET AL., 1986
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	0	20.0000 NEAU ET AL., 1982
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	-	34.0000 CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	0	70.0000 NEAU ET AL., 1982
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	-	100.0000 CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	100.0000 CANTER ET AL., 1986

t-BUTYLPHENYL GLYCIDYL ETHER
3101-60-8

25-OCT-89




APPENDIX 2

491

O-CRESYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	17.0000	CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	17.0000	CANTER ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	0.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0.0000	CANTER ET AL., 1986




APPENDIX 2

493

P-CRESYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			MM	M (LED OR HID)	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	17.0000	CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	17.0000	CANTER ET AL., 1986
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	0.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0.0000	CANTER ET AL., 1986



APPENDIX 2

495


NEOPENTYLGlyCOL DIGLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE NM M (LED OR HID)	REFERENCE
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	167.0000	CANTER ET AL., 1986
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	167.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0.0000	CANTER ET AL., 1986
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	+	0.0000	CANTER ET AL., 1986

NEOPENTYLGLYCOL DIGLYCIDYL ETHER

17557-23-2

25-OCT-89




APPENDIX 2

497

PHENYL GLYCIDYL ETHER

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM M	DOSE (LED OR HID)	REFERENCE	
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	17.0000	CANTER ET AL., 1986	
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	30.0000	IVIE ET AL., 1980	
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	25.0000	SEILER, 1984	
G	SAO	S. TYPHIMURIUM TA100, REVERSE MUTATION	+	25.0000	GREENE ET AL., 1979	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	17.0000	CANTER ET AL., 1986	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	25.0000	IVIE ET AL., 1980	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	+	2.5000	GREENE ET AL., 1979	
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	0	250.0000	IVIE ET AL., 1980
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	-	250.0000	GREENE ET AL., 1979
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	-	250.0000	GREENE ET AL., 1979
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	500.0000	CANTER ET AL., 1986
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0	250.0000	IVIE ET AL., 1980
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	-	250.0000	GREENE ET AL., 1979
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	+	+	0.0000	CANTER ET AL., 1986
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	+	0	0.0000	HEMMINKI ET AL., 1980
G	GCO	MUTATION, CHO CELLS IN VITRO	-	0	25.0000	GREENE ET AL., 1979
C	CIC	CHROM ABERR, CHINESE HAMSTER CELLS IN VITRO	-	0	25.0000	SEILER, 1984
T	TCS	CELL TRANSFORMATION, SHE, CLONAL ASSAY	+	0	6.5000	GREENE ET AL., 1979
T	T7S	CELL TRANSFORMATION, SA7/SHE CELLS	+	0	1.6000	GREENE ET AL., 1979
H	HMM	HOST-MEDIATED ASSAY, MICROBIAL CELLS	+	0	2500.0000	GREENE ET AL., 1979
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	-	0	1000.0000	SEILER, 1984
C	CBA	CHROM ABERR, ANIMAL BONE MARROW IN VIVO	-	0	2.0000	TERRILL ET AL., 1982
C	DLR	DOMINANT LETHAL TEST, RATS	-	0	2.0000	TERRILL ET AL., 1982




APPENDIX 2

499

PHENOL

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	250.0000	POOL & LIN, 1982	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	282.0000	FLORIN ET AL., 1980	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	- 0	2000.0000	KINOSHITA ET AL., 1981	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	1500.0000	KAZMER ET AL., 1983	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	0.0000	COTRUVO ET AL., 1977	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	- 0	2500.0000	THOMPSON & MELAMPY 453, 1981	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	-	1250.0000	HAWORTH ET AL., 1983	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	250.0000	POOL & LIN, 1982	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	282.0000	FLORIN ET AL., 1980	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- 0	50.0000	GILBERT ET AL., 1980	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	0.0000	COTRUVO ET AL., 1977	
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	-	1250.0000	HAWORTH ET AL., 1983	
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	250.0000	POOL & LIN, 1982	
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	282.0000	FLORIN ET AL., 1980	
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	0.0000	COTRUVO ET AL., 1977	
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	-	1250.0000	HAWORTH ET AL., 1983	
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	250.0000	POOL & LIN, 1982	
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- 0	25.0000	GILBERT ET AL., 1980	
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	0.0000	COTRUVO ET AL., 1977	
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	-	1250.0000	HAWORTH ET AL., 1983	
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	282.0000	FLORIN ET AL., 1980	
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	2350.0000	POOL & LIN, 1982	
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- (+)	2350.0000	GOCKE ET AL., 1981	
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	-	0.0000	COTRUVO ET AL., 1977	
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	-	0.0000	COTRUVO ET AL., 1977	
A	ANN	A. NIDULANS, ANEUPLOIDY	(+)	0	1412.0000	CREBELLI ET AL., 1987
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	- 0	4700.0000	GOCKE ET AL., 1981	
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	- 0	20000.0000	STURTEVANT, 1952	
G	DMX	D. MELANOGASTER, SEX-LINKED RECESSIVES	- 0	5250.0000	WOODRUFF ET AL., 1985	
D	DIA	STRAND BREAKS/X-LINKS, ANIMAL CELLS IN VITRO	- 0	94.0000	PELLACK-WALKER & BLUMER, 1986	
G	G9H	MUTATION, CHL V79 CELLS, HPRT	+ 0	250.0000	PASCHIN & BAHITOVA, 1982	
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	(+)	0	94.0000	MORIMOTO & WOLFF, 1980b
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	- 0	2.0000	JANSSON ET AL., 1986	
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	+ 0	0.0050	EREXSON ET AL., 1985a	
S	SHL	SCE, HUMAN LYMPHOCYTES IN VITRO	+ +	3.0000	MORIMOTO ET AL., 1983	
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	- 0	250.0000	GAD-EL, SADA	
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	+ 0	265.0000	CIRANNI ET AL., 1988	
M	MVM	MICRONUCLEUS TEST, MICE IN VIVO	- 0	188.0000	GOCKE ET AL., 1981	
I	ICR	INHIBIT CELL COMMUNICATION, ANIMAL CELLS	- 0	300.0000	MALCOLM ET AL., 1985	
I	ICR	INHIBIT CELL COMMUNICATION, ANIMAL CELLS	- 0	0.0000	CHEN ET AL., 1984	



APPENDIX 2

501


ANTIMONY TRIOXIDE

END POINT	TEST CODE	TEST SYSTEM	RESULTS NM	DOSE M (LED OR HID)	REFERENCE
D	BSD	B. SUBTILIS REC, DIFFERENTIAL TOXICITY	+	0 720.0000	KANEMATSU ET AL., 1980

ANTIMONY TRIOXIDE

1309-64-4

25-OCT-89




APPENDIX 2

503

TITANIUM DIOXIDE

END POINT	TEST CODE	TEST SYSTEM	RESULTS	DOSE	REFERENCE
			NM	M (LED OR HID)	
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	167.0000	ZEIGER ET AL., 1988
G	SA0	S. TYPHIMURIUM TA100, REVERSE MUTATION	- -	5000.0000	DUNKEL ET AL., 1985
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	5000.0000	DUNKEL ET AL., 1985
G	SA5	S. TYPHIMURIUM TA1535, REVERSE MUTATION	- -	167.0000	ZEIGER ET AL., 1988
G	SA7	S. TYPHIMURIUM TA1537, REVERSE MUTATION	- -	5000.0000	DUNKEL ET AL., 1985
G	SA8	S. TYPHIMURIUM TA1538, REVERSE MUTATION	- -	5000.0000	DUNKEL ET AL., 1985
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	5000.0000	DUNKEL ET AL., 1985
G	SA9	S. TYPHIMURIUM TA98, REVERSE MUTATION	- -	167.0000	ZEIGER ET AL., 1988
G	SAS	S. TYPHIMURIUM (OTHER), REVERSE MUTATION	- -	167.0000	ZEIGER ET AL., 1988
G	ECW	E. COLI WP2 UVRA, REVERSE MUTATION	- -	5000.0000	DUNKEL ET AL., 1985
T	TCS	CELL TRANSFORMATION, SHE, CLONAL ASSAY	- 0	20.0000	DIPAOLO & CASTO, 1979
T	T7S	CELL TRANSFORMATION, SA7/SHE CELLS	- 0	600.0000	CASTO ET AL., 1979



25-OCT-89